Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Invenux Inc
Profile last edited on: 4/24/18      CAGE: 5N7X4      UEI:

Business Identifier: Orphan disease drugs
Year Founded
2000
First Award
2002
Latest Award
2017
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1540 Main Street Suite 218
Windsor, CO 80550
   (970) 227-7289
   N/A
   www.invenux.com
Location: Single
Congr. District: 04
County: Weld

Public Profile

Invenux, LLC is a privately held clinical stage biopharmaceutical company focused on research and development of drugs for orphan diseases. The firm's first drug candidate is SCD-101 for the treatment of sickle cell disease. The primary goal of Invenux is to commercialize orphan drugs like SCD-101 through corporatepartnerships that result in upfront, milestone and royalty payments or the outright sale of Inventux' rights to a pharmaceutical company

Extent of SBIR involvement

User Avatar
Phase I Awards
6
Phase II Awards
1
Conversion Rate
16.67%
Phase I Dollars
$1,474,661
Phase II Dollars
$1,499,750
Total Awarded
$2,974,411

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2017 2 NIH $1,941,809
Project Title: First Clinical Trial of an Anti-Sickling Botanical Drug for Sickle Cell Dise
2017 1 NIH $224,731
Project Title: Identification of the Antisickling Compounds in SCD-101
2017 1 NIH $224,950
Project Title: Crossover Study of an Oral Treatment for Sickle Cell Disease
2013 1 NIH $397,926
Project Title: Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity
2002 1 NIH $99,995
Project Title: New Anti-HIV Agents from Evolutionary Chemistry

Key People / Management

  Bruce Eaton -- Former President and Founder

  Lawrence Melvin -- President

  Daniel T Nieuwlandt

  Robert Swift

  Theodore M Tarasow -- Founder, CSO & VP Chemistry

Company News

May 05 2001
Merck, Millennium, Invenux, and Array BioPharma Participate In 'Outpartnering and Outsourcing in Drug Discovery' Conference
Jan 30 2001
Invenux Appoints Former GlaxoSmithKline Executive Carl A. Pelzel President and Chief Executive Officer